The trial evaluates the combination of cabozantinib and panitumumab in KRAS wild-type metastatic colorectal cancer (CRC) and cabozantinib monotherapy in MET amplified CRC. Given the high unmet need in treatment-refractory CRC, successful outcomes could position this combination as a competitive option in the oncology market. The trial's completion in 2018 suggests that data may be available for further analysis, which could influence strategic partnerships or acquisitions in the oncology space. The involvement of Exelixis indicates potential commercial interest in the cabozantinib franchise, which could enhance market positioning if results are favorable.